Nantes Universite
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
4
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Use of a Genetically Modified Infectious Measles Virus with Enhanced Pro-Apoptotic Properties (Mv-Deltac Virus) in Cancer Therapy (US 10,314,905) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 2 fees due Jan 11 to 16, 2027 · next Jan 11
- 3 fees due Feb 15 to 20, 2027 · next Feb 15
- 2 fees due Mar 10 to 19, 2027 · next Mar 10
- 1 fee due Apr 24, 2027The maintenance fee for Inhibitors of RAC1 and Uses Thereof for Treating Cancers (US 11,795,144) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 4 fees due May 5 to 26, 2027 · next May 5
- 2 fees due Jul 9 to 28, 2027 · next Jul 9
- 1 fee due Aug 20, 2027The maintenance fee for ANTI-CD277 Antibodies (US 11,904,004) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 3 fees due Sep 10 to 17, 2027 · next Sep 10
- 2 fees due Oct 7 to 28, 2027 · next Oct 7
Recent changes
- 5 of the patents on this record were granted since Aug 20, 2026
- 1 term has ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,951,524 | Use of Monoclonal Antibodies Specific to the O-Acetylated Form of GD2 Ganglioside for Treatment of Certain Cancers In force · High confidence | In force | High confidence | |
| US 8,305,794 | Use of lacunar spinels with tetrahedral aggregates of a transition element of the AM4x8 type with an electronic data rewritable non volatile memory, and corresponding material In force · From the USPTO record | In force | From the USPTO record | |
| US 8,975,371 | Novel Melanoma Antigen Peptide and Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,920,555 | Gallium-doped phosphocalcic compounds In force · Low confidence | In force | Low confidence | |
| US 8,915,975 | High-Energy Non-Aqueous Batteries Containing Ion-Conducting Gels, and Method for Preparing and Using Same In force · High confidence | In force | High confidence | |
| US 10,716,838 | ANTI-CD277 Antibodies In force · High confidence | In force | High confidence | |
| US 9,709,501 | Cytological Method Using the Auto Fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Infections In force · High confidence | In force | High confidence | |
| US 9,285,360 | Silylated Biomolecules In force · High confidence | In force | High confidence | |
| US 9,837,607 | Use of Centrosymmetric Mott Insulators in a Resistive Switched Memory for Storing Data In force · High confidence | In force | High confidence | |
| US 11,904,004 | ANTI-CD277 Antibodies In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 94: 6 patents in force now held by others · 11 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
24 pending · 4 abandoned